Biotech | March 21, 2022
Wockhardt and Serum Life Sciences UK partner to manufacture multiple vaccines in UK
The facility will produce 150 million vaccine doses per year
The facility will produce 150 million vaccine doses per year
The USFDA has granted a qualified infectious disease product (QIDP) designation to WCK 6777, which signifies its ability to meet unmet medical needs and facilitates a faster approval process
The facility is spread across 215000 sq. feet and provides super-speciality care
Wockhardt has entered into an agreement with Russian Direct Investment Fund and Enso Healthcare to manufacture and supply Sputnik V and Sputnik Light vaccines against Covid-19
The Board of Directors of Wockhardt have approved the unaudited consolidated financial results for the period ended September 30, 2021.
The company to receive upfront and milestone payments, in addition to royalties
Sputnik V is a two-dose shot and has an efficacy of 91.6% against COVID 19
He has previously served in pivotal HR leadership roles at RPG Life Sciences, Akumentis Healthcare, and Wockhardt
This case report is jointly authored by US clinicians from leading hospitals, Houston Methodist Hospital, Weill Cornell Medical College and Johns Hopkins
Topiramate is indicated as a treatment of epilepsy and migraine
Subscribe To Our Newsletter & Stay Updated
